NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”
Updated
Special Notice from the National Institutes of Health, for work in Maryland. Due Nov 20, 2026, 3:00 PM (UTC-5), 30 days left.
| Agency | National Institutes of Health |
|---|---|
| Office | NIH Nci |
| Notice type | Special Notice |
| Set-aside | None |
| Place of performance | Maryland |
| Posted | Oct 20, 2026 |
| Response deadline | Nov 20, 2026, 3:00 PM (UTC-5) (30 days left) |
| Add the deadline to | Google Calendar · Apple / Outlook (.ics) |
Official notice and attachments
Description
SOLCITATION H27-1001 Description of Work: Frederick National Laboratory for Cancer Research (FNLCR) Operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute requires an Indefinite Delivery/Indefinite Quantity Subcontract for construction services for the Frederick National Laboratory for Cancer Research (FNLCR). To obtain a copy of solicitation H27-1001 and other information concerning this opportunity, please refer to: frederick.cancer.gov/work-us/ve... or contact Matthew Hull (Contracts Manager) at [email protected] For information concerning other opportunities with the FNLCR, please refer to: frederick.cancer.gov/workwithus...
Background Information: Leidos Biomedical Research, Inc. (Leidos Biomed), a subsidiary of Leidos Corporation, a Delaware corporation with offices in Frederick, MD is the Operations and Technical Support (OTS) contractor for the National Cancer Institute at Frederick. The effort to be performed will be part of Leidos Biomed’s Prime Contract 75N91019D00024 that has been issued by the National Cancer Institute, National Institutes of Health, Frederick, MD.
The FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, Government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024 & HHSN261201500003I, which provides Operations and Technical Support (OTS) for the FNLCR.
The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this Special Notice as no information is being requested. Please be advised that any submissions provided, despite that no information is requested, become Government property and will not be returned, nor will there be any ensuing discussions or debriefings.
Responses submitted to this Special Notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any.
Contracting contact
- Matthew Hull · [email protected]
As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.
About the buyer
The National Institutes of Health awarded $5.8 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.